160 related articles for article (PubMed ID: 37024304)
1. Cure of Disseminated Human Lymphoma with [
Longtine MS; Shim K; Hoegger MJ; Benabdallah N; Abou DS; Thorek DLJ; Wahl RL
J Nucl Med; 2023 Jun; 64(6):924-931. PubMed ID: 37024304
[TBL] [Abstract][Full Text] [Related]
2. Cure of Disseminated Human Lymphoma with [
Shim K; Longtine MS; Abou DS; Hoegger MJ; Laforest RS; Thorek DLJ; Wahl RL
J Nucl Med; 2023 Apr; 64(4):542-548. PubMed ID: 36357179
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
4. Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using
Havlena GT; Kapadia NS; Huang P; Song H; Engles J; Brechbiel M; Sgouros G; Wahl RL
J Nucl Med; 2023 Jan; 64(1):109-116. PubMed ID: 35981897
[TBL] [Abstract][Full Text] [Related]
5. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
6. Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of
Lee CH; Lim I; Woo SK; Kim W; Kim KI; Lee KC; Song K; Lim SM
Ann Nucl Med; 2021 May; 35(5):639-647. PubMed ID: 33811601
[TBL] [Abstract][Full Text] [Related]
7. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Candidate Theranostics for
Abou DS; Longtine M; Fears A; Benabdallah N; Unnerstall R; Johnston H; Shim K; Hasson A; Zhang H; Ulmert D; Mangin F; Ozen S; Raibaut L; Brandès S; Meyer M; Chambron JC; Tatum DS; Magda D; Wahl RL; Thorek DLJ
J Nucl Med; 2023 Jul; 64(7):1062-1068. PubMed ID: 37142300
[No Abstract] [Full Text] [Related]
12. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
[TBL] [Abstract][Full Text] [Related]
15. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
16. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Evaluation of CD20 Expression Using
Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
[TBL] [Abstract][Full Text] [Related]
18. Preclinical study of
Durand-Panteix S; Monteil J; Sage M; Garot A; Clavel M; Saidi A; Torgue J; Cogne M; Quelven I
Br J Cancer; 2021 Dec; 125(12):1657-1665. PubMed ID: 34671126
[TBL] [Abstract][Full Text] [Related]
19. A Single Dose of
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Thiele NA; Schlyer D; Wilson JJ; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):649-655. PubMed ID: 30413660
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
